The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS: We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis. RESULTS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Type 1 tumors were associated with MET alterations, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2-antioxidant response element (ARE) pathway. A CpG island methylator phenotype (CIMP) was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase (FH). CONCLUSIONS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renal-cell carcinoma consisted of at least three subtypes based on molecular and phenotypic features. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“another possible mechanism by which D-2-HG drives tumorigenesis is through the promotion of genetic instability, predisposing cells to oncogenic transformation103.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
In the citing paper
“Genomic studies have established that somatic mutations in IDH1 and IDH2 are perhaps the first genetic events to occur during tumorigenesis in human glioma and AML, and appear to initiate pathogenesis by a common mechanism103,115-117.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
In the citing paper
“The most commonly occurring cancers thought to arise from mutant IDH1/2 (mIDH1/2) include glioma, cartilaginous tumours, AML, angioimmunoblastic T cell lymphoma (AITL) and intrahepatic cholangiocarcinoma (ICC).”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Self-citationComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Self-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Flagged first, then by citations
1 of the 42 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Delahunt B, 1997, Mod Pathol, 10, 537
- Schmidt LS, 1998, Cancer Res, 58, 1719
Cited by
Sorted by citations
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
Chandrashekar, D. S., Bashel, B., Balasubramanya, S. A. H., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B. V. S. K., & Varambally, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.05.002 · Cited by 6,086
Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.029 · Cited by 3,157
Hsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.9 · Cited by 2,426
The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis
Yamamoto, M., Kensler, T. W., & Motohashi, H. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2017 · Cited by 1,968
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Towards a general-purpose foundation model for computational pathology
Chen, R. J., Ding, T., Lu, M. Y., Williamson, D. F. K., Jaume, G., Song, A. H., Chen, B., Zhang, A., Shao, D., Shaban, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02857-3 · Cited by 1,560
Landscape of Microsatellite Instability Across 39 Cancer Types
Bonneville, R., Krook, M. A., Kautto, E. A., Miya, J., Wing, M. R., Chen, H., Reeser, J. W., Yu, L., & Roychowdhury, S. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00073 · Cited by 1,505
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,307
Renal Mass and Localized Renal Cancer: AUA Guideline
Campbell, S. C., Uzzo, R. G., Allaf, M. E., Bass, E. B., Cadeddu, J. A., Chang, A., Clark, P. E., Davis, B. J., Derweesh, I., Giambarresi, L. I., et al. (2017) · The Journal of Urology · doi:10.1016/j.juro.2017.04.100 · Cited by 1,262
The chromatin accessibility landscape of primary human cancers
Corces, M. R., Granja, J. M., Shams, S., Louie, B. H., Seoane, J. A., Zhou, W., Silva, T. C., Groeneveld, C., Wong, C. K., Cho, S. W., et al. (2018) · Science · doi:10.1126/science.aav1898 · Cited by 1,230
Self-citationRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Grünwald, V., Gillessen, S., & Horwich, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz056 · Cited by 1,151
BAP1 links metabolic regulation of ferroptosis to tumour suppression
Zhang, Y., Shi, J., Liu, X., Li, F., Gong, Z., Koppula, P., Sirohi, K., Li, X., Wei, Y., Lee, H., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0178-0 · Cited by 1,043
Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Bakir, M. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 967
Moch, H., Amin, M. B., Berney, D. M., Compérat, É., Gill, A. J., Hartmann, A., Menon, S. G., Raspollini, M. R., Rubin, M. A., Srigley, J. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.06.016 · Cited by 932
Zou, Y., Palte, M. J., Deik, A. A., Li, H., Eaton, J. K., Wang, W., Tseng, Y.-Y., Deasy, R., Kost-Alimova, M., Dančík, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09277-9 · Cited by 887
Treatment of renal cell carcinoma: Current status and future directions
Barata, P. C., & Rini, B. I. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21411 · Cited by 828
Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I
Campbell, S. C., Clark, P. E., Chang, S. S., Karam, J. A., Souter, L., & Uzzo, R. G. (2021) · The Journal of Urology · doi:10.1097/ju.0000000000001911 · Cited by 803
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Ricketts, C. J., de Cubas, A. A., Fan, H., Smith, C. C., Lang, M., Reznik, E., Bowlby, R., Gibb, E. A., Akbani, R., Beroukhim, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.075 · Cited by 809
Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors
Young, M. D., Mitchell, T. J., Vieira Braga, F. A., Tran, M. G. B., Stewart, B. J., Ferdinand, J. R., Collord, G., Botting, R. A., Popescu, D.-M., Loudon, K. W., et al. (2018) · Science · doi:10.1126/science.aat1699 · Cited by 762
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Ricketts, C. J., de Cubas, A. A., Fan, H., Smith, C. C., Lang, M., Reznik, E., Bowlby, R., Gibb, E. A., Akbani, R., Beroukhim, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.032 · Cited by 739
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
Clark, D. J., Dhanasekaran, S. M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost, F., Reva, B., Lih, T.-S. M., Chang, H.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.007 · Cited by 730
Pan-cancer image-based detection of clinically actionable genetic alterations
Kather, J. N., Heij, L. R., Grabsch, H. I., Loeffler, C. M. L., Echle, A., Muti, H. S., Krause, J., Niehues, J., Sommer, K. A. J., Bankhead, P., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0087-6 · Cited by 686
The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
Linehan, W. M., & Ricketts, C. J. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0211-5 · Cited by 644
Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition
Sciacovelli, M., Gonçalves, E., Johnson, T. I., Zecchini, V. R., da Costa, A. S. H., Gaude, E., Drubbel, A. V., Theobald, S. J., Abbo, S. R., Tran, M. G. B., et al. (2016) · Nature · doi:10.1038/nature19353 · Cited by 584
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B. J., Porta, C., Schmidinger, M., Rioux-Leclercq, N. C., Bex, A., Khoo, V. S., Gruenvald, V., & Horwich, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw328 · Cited by 504
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification
Kamps, R., Brandão, R. D., van den Bosch, B. J. C., Paulussen, A. D. C., Xanthoulea, S., Blok, M. J., & Romano, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020308 · Cited by 472
The immunology of renal cell carcinoma
Diaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 447
TFEB and TFE3: Linking Lysosomes to Cellular Adaptation to Stress
Raben, N., & Puertollano, R. (2016) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-111315-125407 · Cited by 437
Coupling Krebs cycle metabolites to signalling in immunity and cancer
Ryan, D. G., Murphy, M. P., Frezza, C., Prag, H. A., Chouchani, E. T., O’Neill, L. A., & Mills, E. L. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0014-7 · Cited by 398
Tannir, N. M., Jonasch, E. W., Albiges, L. K., Altinmakas, E., Ng, C. S., Matin, S. F., Wang, X., Qiao, W., Lim, Z. D., Tamboli, P., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.10.049 · Cited by 366
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
Chen, F., Zhang, Y., Şenbabaoğlu, Y., Ciriello, G., Yang, L., Reznik, E., Shuch, B., Micevic, G., de Velasco, G., Shinbrot, E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.024 · Cited by 367
The Metabolic Basis of Kidney Cancer
Linehan, W. M., Schmidt, L. S., Crooks, D. R., Wei, D., Srinivasan, R., Lang, M., & Ricketts, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1354 · Cited by 350
Fumarate induces vesicular release of mtDNA to drive innate immunity
Zecchini, V. R., Paupe, V., Herranz-Montoya, I., Janssen, J. J. E., Wortel, I. M. N., Morris, J. L., Ferguson, A., Chowdhury, S. R., Segarra‐Mondejar, M., Costa, A. S. H., et al. (2023) · Nature · doi:10.1038/s41586-023-05770-w · Cited by 342
MET-dependent solid tumours — molecular diagnosis and targeted therapy
Guo, R., Luo, J., Chang, J. C., Rekhtman, N., Arcila, M. E., & Drilon, A. E. D. C. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0377-z · Cited by 333
Dudani, S., de Velasco, G., Wells, J. C., Gan, C. L., Donskov, F. N., Porta, C., Fraccon, A. P., Pasini, F., Lee, J., Hansen, A. R., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.21869 · Cited by 335
TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages
Silva, T. C., Colaprico, A., Olsen, C., D’Angelo, F., Bontempi, G., Ceccarelli, M., & Noushmehr, H. (2016) · F1000Research · doi:10.12688/f1000research.8923.1 · Cited by 303
Ericksen, R. E., Lim, S. L., McDonnell, E., Shuen, W. H., Vadiveloo, M. K., White, P. J., Ding, Z., Kwok, R., Lee, P., Radda, G. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.020 · Cited by 302
Pal, S. K., Tangen, C. M., Thompson, I. M., Haas, N. B., George, D. J., Heng, D. Y. C., Shuch, B. M., Stein, M. N., Tretiakova, M., Humphrey, P. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00152-5 · Cited by 291
DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis
Papanicolau‐Sengos, A., & Aldape, K. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042220-022304 · Cited by 285
SCINA: A Semi-Supervised Subtyping Algorithm of Single Cells and Bulk Samples
Zhang, Z., Luo, D., Zhong, X. Y., Choi, J. H., Ma, Y., Wang, S., Mahrt, E., Guo, W., Stawiski, E. W., Modrusan, Z. D., et al. (2019) · Genes · doi:10.3390/genes10070531 · Cited by 285
DNA methylation in mammalian development and disease
Smith, Z. D., Hetzel, S., & Meissner, A. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00760-8 · Cited by 310
Trpkov, K., Hes, O., Williamson, S. R., Adeniran, A., Agaimy, A., Alaghehbandan, R., Amin, M. B., Argani, P., Chen, Y., Liang Cheng, C., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00779-w · Cited by 275
Choosing the right cell line for renal cell cancer research
Brodaczewska, K. K., Szczylik, C. A., Fiedorowicz, M., Porta, C., & Czarnecka, A. M. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0565-8 · Cited by 279
Trpkov, K., Hes, O., Agaimy, A., Bonert, M., Martínek, P., Magi‐Galluzzi, C., Kristiansen, G., Lüders, C., Nesi, G., Compérat, É., et al. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000617 · Cited by 260
Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review)
Ahmad, R., Singh, J. K., Wunnava, A., Al-Obeed, O. A., Abdulla, M., & Srivastava, S. K. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4847 · Cited by 265
Tabibu, S., Vinod, P. K. U., & Jawahar, C. V. (2019) · Scientific Reports · doi:10.1038/s41598-019-46718-3 · Cited by 261
Warren, A. Y., & Harrison, D. J. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2447-8 · Cited by 242
Towards individualized therapy for metastatic renal cell carcinoma
Kotecha, R. R., Motzer, R. J., & Voss, M. H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0209-1 · Cited by 236
Targeting MET Dysregulation in Cancer
Recondo, G., Che, J., Janne, P. A., & Awad, M. M. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1446 · Cited by 235
Chang, S., Yim, S., & Park, H. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0230-6 · Cited by 228
Immunotherapy in Renal Cell Carcinoma: The Future Is Now
Deleuze, A., Saout, J., Dugay, F., Peyronnet, B., Mathieu, R., Verhoest, G., Bensalah, K., Crouzet, L., Laguerre, B., Belaud-Rotureau, M.-A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072532 · Cited by 198
Telonis, A. G., Magee, R. G., Loher, P., Chervoneva, I., Londin, E. R., & Rigoutsos, I. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx082 · Cited by 219
Oncometabolites in renal cancer
Yong, C., Stewart, G. D., & Frezza, C. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0210-z · Cited by 216
Metabolic reprogramming in renal cancer: Events of a metabolic disease
Chakraborty, S., Balan, M., Sabarwal, A., Choueiri, T. K., & Pal, S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188559 · Cited by 214
Ge, T., Gu, X., Jia, R., Ge, S., Chai, P., Zhuang, A., & Fan, X. (2022) · 癌症：英文版 · doi:10.1002/cac2.12374 · Cited by 220
NRF2: KEAPing Tumors Protected
Pillai, R., Hayashi, M., Zavitsanou, A.-M., & Papagiannakopoulos, T. Y. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0922 · Cited by 196
Hsieh, J. J.-D., Le, V. H., Oyama, T., Ricketts, C. J., Ho, T. H., & Cheng, E. H. Y. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2549 · Cited by 194
Chen, Y., Xu, J., Skanderup, A. J., Dong, Y., Brannon, A. R., Wang, L., Won, H. H., Wang, P. I., Nanjangud, G. J., Jungbluth, A. A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13131 · Cited by 184
Efficacy of Savolitinib vs Sunitinib in Patients WithMET-Driven Papillary Renal Cell Carcinoma
Choueiri, T. K., Heng, D. Y. C., Lee, J., Cancel, M., Verheijen, R. B., Mellemgaard, A., Ottesen, L. H., Frigault, M. M., L’Hernault, A., Szíjgyártó, Z., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2218 · Cited by 179
Oncometabolites: Unconventional triggers of oncogenic signalling cascades
Sciacovelli, M., & Frezza, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.025 · Cited by 184
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer
Choueiri, T. K., Plimack, E. R., Arkenau, H., Jonasch, E., Heng, D. Y. C., Powles, T. B., Frigault, M. M., Clark, E. A., Handzel, A. A., Gardner, H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2967 · Cited by 177
Systemic treatment of renal cell cancer: A comprehensive review
Sánchez-Gastaldo, A., Kempf, E., del Alba, A. G., & Durán, I. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.010 · Cited by 178
Chanzá, N. M., Xie, W., Bilen, M. A., Dzimitrowicz, H. E., Burkart, J. T., Geynisman, D. M., Balakrishnan, A., Bowman, I. A., Jain, R., Stadler, W. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30907-0 · Cited by 173
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
Jin, J., Xie, Y., Zhang, J.-S., Wang, J., Dai, S.-J., He, W., Li, S.-Y., Ashby, C. R., Chen, Z., & He, Q. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100929 · Cited by 185
Genomic profiling in renal cell carcinoma
Dizman, N., Philip, E. J., & Pal, S. K. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0301-x · Cited by 171
Gene set enrichment analysis for genome-wide DNA methylation data
Maksimovic, J., Oshlack, A., & Phipson, B. (2021) · Genome biology · doi:10.1186/s13059-021-02388-x · Cited by 182
Fumarate hydratase in cancer: A multifaceted tumour suppressor
Schmidt, C., Sciacovelli, M., & Frezza, C. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.002 · Cited by 166
Xu, W., Xu, M., Wang, L., Zhou, W., Xiang, R., Shi, Y., Zhang, Y., & Piao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0081-6 · Cited by 162
TFEB-amplified Renal Cell Carcinomas
Argani, P., Reuter, V. E., Zhang, L., Sung, Y., Ning, Y., Epstein, J. I., Netto, G. J., & Antonescu, C. R. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000720 · Cited by 161
Metastasis in renal cell carcinoma: Biology and implications for therapy
Gong, J., Maia, M. C., Dizman, N., Govindarajan, A., & Pal, S. K. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.08.006 · Cited by 161
Genetic predisposition to kidney cancer
Schmidt, L. S., & Linehan, W. M. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.09.001 · Cited by 163
Inamura, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102195 · Cited by 164
Epigenetics in renal cell cancer: mechanisms and clinical applications
Joosten, S. C., Smits, K. M., Aarts, M. J. B., Melotte, V., Koch, A., Tjan‐Heijnen, V. C. G., & van Engeland, M. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0023-z · Cited by 166
MiT/TFE Family of Transcription Factors, Lysosomes, and Cancer
Perera, R. M., Malta, C. D., & Ballabio, A. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055835 · Cited by 162
DiseaseMeth version 2.0: a major expansion and update of the human disease methylation database
Xiong, Y., Wei, Y., Gu, Y., Zhang, S., Lyu, J., Zhang, B., Chen, C., Zhu, J., Wang, Y., Liu, H., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1123 · Cited by 153
Papillary Renal Cell Carcinoma (PRCC): An Update
Akhtar, M., Al‐Bozom, I., & Hussain, T. O. A. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000220 · Cited by 151
MET alterations in NSCLC—Current Perspectives and Future Challenges
Remón, J., Hendriks, L. E. L., Mountzios, G., García‐Campelo, R., Saw, S. P. L., Uprety, D., Recondo, G., Villacampa, G. J., & Reck, M. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.10.015 · Cited by 156
Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci
Smith, S. C., Trpkov, K., Chen, Y., Mehra, R., Sirohi, D., Ohe, C., Cani, A. K., Hovelson, D. H., Omata, K., McHugh, J. B., et al. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000719 · Cited by 150
New and emerging renal entities: a perspective post‐ WHO 2016 classification
Trpkov, K., & Hes, O. (2018) · Histopathology · doi:10.1111/his.13727 · Cited by 147
Mitochondrial complex I promotes kidney cancer metastasis
Bezwada, D., Perelli, L., Lesner, N. P., Cai, L., Brooks, B., Wu, Z., Vu, H., Sondhi, V., Cassidy, D. L., Kasitinon, S. Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07812-3 · Cited by 158
Chen, Y., Mirsadraei, L., Jayakumaran, G., Al‐Ahmadie, H. A., Fine, S. W., Gopalan, A., Sirintrapun, S. J., Tickoo, S. K., & Reuter, V. E. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001170 · Cited by 145
Msaouel, P., Malouf, G. G., Su, X., Yao, H., Tripathi, D. N., Soeung, M., Gao, J., Rao, P., Coarfa, C., Creighton, C. J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2020.04.002 · Cited by 148
Pro-inflammatory and proliferative microglia drive progression of glioblastoma
Liu, H., Sun, Y., Zhang, Q., Jin, W., Gordon, R. E., Zhang, Y., Wang, J., Sun, C., Wang, Z., Qi, X., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109718 · Cited by 144
Fernandéz‐Pello, S., Hofmann, F., Tahbaz, R., Marconi, L. S., Lam, T. B. L., Albiges, L. K., Bensalah, K., Canfield, S. E., Dabestani, S., Giles, R. H., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.11.020 · Cited by 144
Muller, M., Ferlicot, S., Guillaud-Bataille, M., Teuff, G. L., Genestie, C., DeVeaux, S., Slama, A., Poulalhon, N., Escudier, B. J., Albiges, L. K., et al. (2017) · Clinical Genetics · doi:10.1111/cge.13014 · Cited by 145
Spatial heterogeneity in medulloblastoma
Morrissy, A. S., Cavalli, F. M. G., Remke, M., Ramaswamy, V., Shih, D. J. H., Holgado, B., Farooq, H., Donovan, L., Garzia, L., Agnihotri, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3838 · Cited by 143
Re‐evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients
Li, Y., Reuter, V. E., Matoso, A., Netto, G. J., Epstein, J. I., & Argani, P. (2017) · Histopathology · doi:10.1111/his.13395 · Cited by 136
The translational potential of microRNAs as biofluid markers of urological tumours
Fendler, A., Stephan, C., Yousef, G. M., Kristiansen, G., & Jung, K. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.193 · Cited by 135
Lau, H. D., Chan, E., Fan, A. C., Kunder, C. A., Williamson, S. R., Zhou, M., Idrees, M. T., Maclean, F. M., Gill, A. J., & Kao, C. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001372 · Cited by 133
Malouf, G. G., Ali, S. M., Wang, K., Balasubramanian, S., Ross, J. S., Miller, V. A., Stephens, P. J., Khayat, D., Pal, S. K., Su, X., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.01.051 · Cited by 133
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
McKay, R. R., Bossé, D., Xie, W., Wankowicz, S. A. M., Flaifel, A., Moreira, R. B., Lalani, A. A., Martini, D. J., Wei, X. X., Braun, D. A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0475 · Cited by 130
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
Mina, M., Raynaud, F., Tavernari, D., Battistello, E., Sungalee, S., Saghafinia, S., Laessle, T., Sanchez-Vega, F., Schultz, N., Oricchio, E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.010 · Cited by 129
Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma
Casuscelli, J., Weinhold, N., Gundem, G., Wang, L., Zabor, E. C., Drill, E. N., Wang, P. I., Nanjangud, G. J., Redzematovic, A., Nargund, A. M., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92688 · Cited by 131
Cohesin mutations in human cancer
Hill, V. K., Kim, J.-S., & Waldman, T. A. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.05.002 · Cited by 137
Papillary Renal Neoplasm With Reverse Polarity
Al‐Obaidy, K. I., Eble, J. N., Liang Cheng, C., Williamson, S. R., Sakr, W., Gupta, N., Idrees, M. T., & Grignon, D. J. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001288 · Cited by 128
The epigenetic landscape of renal cancer
Morris, M. R., & Latif, F. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.168 · Cited by 129
Network-based machine learning and graph theory algorithms for precision oncology
Zhang, W., CHIEN, J. R., Yong, J., & Kuang, R. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0029-7 · Cited by 137
Hsieh, J. J.-D., Le, V., Cao, D., Cheng, E. H. Y., & Creighton, C. J. (2017) · The Journal of Pathology · doi:10.1002/path.5022 · Cited by 131
Integrative clinical and molecular characterization of translocation renal cell carcinoma
Bakouny, Z., Sadagopan, A., Ravi, P. K., Metaferia, N. Y., Li, J., AbuHammad, S., Tang, S., Denize, T., Garner, E. R., Gao, X. Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110190 · Cited by 123
Nassar, A. H., Adib, E., Abou Alaiwi, S., El Zarif, T., Groha, S., Akl, E. W., Nuzzo, P. V., Mouhieddine, T. H., Perea-Chamblee, T., Taraszka, K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.022 · Cited by 121
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- The Cancer Genome Atlas Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-01-14
- Volume
- 374
- Issue
- 2
- Pages
- 135-145
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4775252
- OpenAlex
- W2111867681
- Cited by
- 1,336
- References
- 42
- Citations by year
- 2026: 60 · 2025: 100 · 2024: 95 · 2023: 130 · 2022: 135 · 2021: 159 · 2020: 153 · 2019: 151 · 2018: 128 · 2017: 126 · 2016: 96
- FWCI
- 92.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (K24CA172355, U24CA143882, U24CA143843, U24CA143840, U24CA143858, U24CA144025, U24CA143866, U24CA199461, U24CA143883, U24CA143845, U24CA180951, U24CA143867, R01CA169172, U24CA143848, U24CA143799, U24CA143835, P30CA008748, P30CA015083, P30CA016672, P30CA016056, P30CA016086)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- papillary renal cell carcinoma, type 2 papillary renal cell carcinoma, MET alterations, SETD2 mutation, TFE3 fusion, Nrf2/ARE pathway, CpG island methylator phenotype, tumor subtypes, prognosis, molecular heterogeneity
- MeSH terms
- Carcinoma, Papillary, Humans, Kidney Neoplasms, Mutation, Phenotype, RNA, Messenger, RNA, Neoplasm, Signal Transduction, Sequence Analysis, RNA, CpG Islands, DNA Methylation, Proto-Oncogene Proteins c-met, MicroRNAs, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
